Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

Inclusion Criteria: * Patients ≥ 18 years at the time of consent * Patients with evidence of resistant or relapsed complement-mediated aHUS with symptoms of Thrombocytopenia, hemolysis, ongoing Thrombotic Microangiopathy and acute kidney injury. * Evidence of ongoing Thrombotic Microangiopathy which includes Haptoglobin \<LLN or undetectable and/or presence of schistocytes * Acute kidney injury (proteinuria/creatinuria \> ULN and/or reduced eGFR) * Platelets less than 150,000 per microliter (Thrombocytopenia) * Anemia (Hemoglobin ≤10 g/dL) due to hemolysis * Lactate dehydrogenase (LDH) level ≥ 1.5 times the upper limit of normal (xULN) during Screening * All patients must be vaccinated prior to dosing with MenACWY Menactra® polysaccharide diphtheria toxoid conjugate vaccination against Neisseria meningitidis serogroups A, C, Y, and W-135 and MenB meningococcal serogroup B vaccine (Bexsero®). If the window of vaccination is short, then patients will be prophylactically treated with appropriate antibiotics * Willing and able to understand and complete informed consent procedures, including signing and dating the informed consent form (ICF), and comply with the study visit schedule. * Male patients and partners of child-bearing potential must agree to use contraceptives and male patients must agree to refrain from donating sperm for the duration of the study. * Female partners of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant,…